⌘K
Loading ticker…
As of 2026-08-21, Ocular Therapeutix, Inc. (OCUL) has a 3-month relative strength percentile of 89 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 55. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.9%, relative volume 1.08×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
OCUL is held by 17 ETFs as of May 2026. Top owner: VTWO at 0.05% weight, $9M notional. Top 3 carry $21M.
Held by 43 ETFs · $183M across latest filings · largest weight 3.07% (PJP).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.05% | $9M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.03% | $8M | — |
| VHTVanguard Health Care ETF | 0.02% | $4M | — |
| VTWG | 0.09% | $2M | −0.01 pp |
| ESML | 0.06% | $1M | +0.03 pp |
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $898K |
| — |
| ONEQ | 0.01% | $648K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $143K | — |
| IBBQ | 0.16% | $105K | +0.02 pp |
| ITWO | 0.04% | $80K | — |
Showing 10 of 17 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | OCUL Jan avg: 3.39% median: -0.43% win: 50% σ: 27.53% n: 4 2022-04-12 → 2026-07-31 | OCUL Feb avg: 38.00% median: 26.14% win: 50% σ: 53.84% n: 4 2022-04-12 → 2026-07-31 | OCUL Mar avg: -6.22% median: -7.40% win: 25% σ: 6.67% n: 4 2022-04-12 → 2026-07-31 | OCUL Apr avg: -4.64% median: 10.63% win: 60% σ: 27.70% n: 5 2022-04-12 → 2026-07-31 | OCUL May avg: 0.76% median: -3.49% win: 40% σ: 12.21% n: 5 2022-04-12 → 2026-07-31 | OCUL Jun avg: 10.78% median: 15.86% win: 80% σ: 18.27% n: 5 2022-04-12 → 2026-07-31 | OCUL Jul avg: 6.22% median: 11.44% win: 60% σ: 19.62% n: 5 2022-04-12 → 2026-07-31 | OCUL Aug avg: 1.59% median: 4.85% win: 75% σ: 12.87% n: 4 2022-04-12 → 2026-07-31 (current) | OCUL Sep avg: -10.21% median: -10.60% win: 0% σ: 8.65% n: 4 2022-04-12 → 2026-07-31 | OCUL Oct avg: -0.37% median: -4.75% win: 25% σ: 15.24% n: 4 2022-04-12 → 2026-07-31 | OCUL Nov avg: -8.15% median: -9.53% win: 25% σ: 9.52% n: 4 2022-04-12 → 2026-07-31 | OCUL Dec avg: 15.18% median: -2.73% win: 25% σ: 43.47% n: 4 2022-04-12 → 2026-07-31 |